Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization

G. Dangas, A. Colombo

Research output: Contribution to journalArticlepeer-review


Coronary dissections and intracoronary thrombosis are the most important determinants of acute and subacute complications occurring during coronary interventions. Stents have proved efficacious to repair coronary dissections. The formation of intracoronary thrombi during percutaneous coronary intervention (PCI), the other main pathogenic mechanism for acute complications of PCI, has also been implicated in the pathogenesis of long- term ischemic outcomes. To reduce intracoronary thrombosis, all PCIs have been historically performed during intense short-term anticoagulation with the combination of unfractionated heparin plus aspirin. Compelling data on the central role of platelets in arterial thrombosis have made apparent the need for more potent antiplatelet agents for the treatment of patients undergoing PCI.

Original languageEnglish
JournalAmerican Heart Journal
Issue number1 II
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization'. Together they form a unique fingerprint.

Cite this